Table 2.
List of therapeutic strategies targeting ESM-1.
| Intervention | Cancer type | Results | Reference |
|---|---|---|---|
| siRNA | Colorectal Cancer | Inhibit migration,invasion and decrease cell survival | (26, 54) |
| Hepatocellular carcinoma | Decrease cell survival, migration, and invasion and modulated cell cycle progression | (28) | |
| Head and neck cancer | Inhibit proliferation, migration | (81) | |
| Invasive Bladder Cancer | Inhibit VEGF-A–induced tube formation, migration, and VEGFR-2 phosphorylation | (48) | |
| Gastric cancer | Inhibit proliferation | (62) | |
| Proatate cancer | Inhibit migration | (73, 82) | |
| Triple-negative breast cancer |
Inhibit proliferation, colony, migration, invasion | (83) | |
| shRNA | Oral squamous cell carcinoma | Inhabit NGFR-induced the tumor growth, invasion, and metastasis | (84) |
| Antibody (PABsc-20343) |
Gastric cancer | Inhibit tumor cells and vascular endothelial cells proliferation | (29) |
| miR-9-3p | Bladder cancer | Inhibit viability, migration, and invasion, and promote apoptosis | (85) |
VEGF-A, Vascular endothelial growth factor A; VEGFR-2, Vascular endothelial growth factor receptor 2; NGFR, Nerve growth factor receptor.